Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ketamine for memory reconsolidation in treatment-resistant PTSD
ACTRN12626000603314Phase 2Not yet recruiting
- Sponsor
- University of the Sunshine Coast
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Ketamine arm with Midazolam active placebo arm (2 arms). Primary endpoint: Change in CAPS-5 total score from baseline to Week 18. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12626000603314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000603314.